Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa

To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub–Saharan Africa (SSA) for a range of program situations. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Andrew N., Stover, John, Cambiano, Valentina, Nakagawa, Fumiyo, Jordan, Michael R., Pillay, Deenan, Doherty, Meg, Revill, Paul, Bertagnolio, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451603/
https://www.ncbi.nlm.nih.gov/pubmed/28329236
http://dx.doi.org/10.1093/infdis/jix089
Descripción
Sumario:To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub–Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016–2030 will be attributable to HIVDR.

Ejemplares similares